Nasus Pharma (NSRX) Liabilities from Discontinued Operations (2024 - 2025)
Nasus Pharma (NSRX) reported Liabilities from Discontinued Operations of 483000.0 for Q4 2025, down 1.23% on a YoY basis from 489000.0 in Q4 2024, and down 11.7% quarter-over-quarter from 547000.0 in Q2 2025.
Nasus Pharma (NSRX) Liabilities from Discontinued Operations (2024 - 2025) Analysis & Trends
Nasus Pharma has reported Liabilities from Discontinued Operations for 2 years, with the latest figure at 483000.0 in Q4 2025.
- For the quarter ending Q4 2025, Liabilities from Discontinued Operations fell 1.23% year-over-year to 483000.0; the trailing twelve-month figure through Dec 2025 stood at 483000.0 (down 1.23% YoY), and the FY2025 full-year result was 483000.0, down 1.23% from the prior year.
- Liabilities from Discontinued Operations for Q4 2025 stood at 483000.0, down from 547000.0 in the prior quarter.
- The five-year high for Liabilities from Discontinued Operations was 547000.0 in Q2 2025, with the low at 483000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Nasus Pharma | 23.47 Mn | 19.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 483,000.00 |
| Dec 31, 2025 | 483,000.00 |
| Jun 30, 2025 | 547,000.00 |
| Jun 30, 2025 | 547,000.00 |
| Dec 31, 2024 | 489,000.00 |
| Dec 31, 2024 | 489,000.00 |